Recent Updates
Recently added Catalysts
SPTX Positive Sentiment

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Key Takeaway: Seaport Therapeutics announced its participation in two upcoming investor conferences in March 2025. The management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference and present at the Stifel 2025 Virtual CNS Forum. This highlights the company's commitment to advancing its neuropsychiatric drug development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seaport Therapeutics is advancing novel neuropsychiatric medicines.
  • Participation in major investor conferences indicates strong investor interest.
  • The company has a proven strategy and experienced management team.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

BOSTON, March 3, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences in March:
• Leerink Partners Global Healthcare Conference 2025 The Seaport management team was invited to participate in one-on-one meetings at the conference on March 10-12 th in Miami, FL.
• The Seaport management team was invited to participate in one-on-one meetings at the conference on March 10-12 th in Miami, FL.
• Stifel 2025 Virtual CNS Forum The Seaport management team was invited to present on Wednesday, March 19 th at 2:00 – 2:25pm EDT. The live and archived webcast will be available under the Events section of the Company’s website at https://seaporttx.com/news-papers/ .
• The Seaport management team was invited to present on Wednesday, March 19 th at 2:00 – 2:25pm EDT. The live and archived webcast will be available under the Events section of the Company’s website at https://seaporttx.com/news-papers/ .
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph TM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com .

Frequently Asked Questions

What conferences will Seaport Therapeutics attend?

Seaport Therapeutics will attend the Leerink Partners Global Healthcare Conference and the Stifel 2025 Virtual CNS Forum.

When is Seaport's presentation at the Stifel Forum?

Seaport's presentation at the Stifel 2025 Virtual CNS Forum is scheduled for March 19, 2025, from 2:00 to 2:25 PM EDT.

Where can I find the webcast of Seaport's presentation?

The live and archived webcast will be available on Seaport's website under the Events section.

What is the focus of Seaport Therapeutics?

Seaport Therapeutics focuses on advancing novel neuropsychiatric medicines to address high unmet patient needs.

Last updated: Mar 3, 2025